202.46  -1.04 (-0.51%)		04-07 16:00
Open: 198.1 High: 206.69 Volume: 930,144		Pre. Close: 203.5 Low: 198.1 Market Cap: 14,252(M)

Short term
Mid term
Targets	6-month :	267.11	1-year :	289.19
Resists	First :	228.69	Second :	247.6
Pivot price	216.43
Supports	First :	198.1	Second :	164.81
MAs	MA(5) :	205.42	MA(20) :	220.21
	MA(100) :	269.36	MA(250) :	291.25
MACD	MACD :	-10.8	Signal :	-9.8
%K %D	K(14,3) :	7.1	D(3) :	7.9
RSI	RSI(14): 25.2
52-week	High :	354.88	Low :	198.1

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PODD ] has closed above bottom band by 16.5%. Bollinger Bands are 30.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	207 - 208.45	208.45 - 209.56
Low:	194.38 - 196.31	196.31 - 197.79
Close:	199.76 - 202.4	202.4 - 204.43

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Tue, 07 Apr 2026
Insulet (PODD) Gets Downgraded by Citigroup; Price Target Lowered | PODD Stock News - GuruFocus

Tue, 07 Apr 2026
Insulet (PODD) Appoints Mike Panos as Chief Commercial Officer - Insider Monkey

Tue, 07 Apr 2026
Insulet (PODD) Appoints Mike Panos as Chief Commercial Officer - Yahoo Finance

Tue, 07 Apr 2026
Insulet (NASDAQ:PODD) Cut to Neutral at Citigroup - marketbeat.com

Tue, 07 Apr 2026
Citi Downgrades Insulet Corporation (PODD) to Neutral - StreetInsider

Mon, 06 Apr 2026
Robust 2025 growth, new leadership in Insulet (NASDAQ: PODD) 2026 proxy - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Devices
Shares Out	70 (M)
Shares Float	70 (M)
Held by Insiders	0.3 (%)
Held by Institutions	103 (%)
Shares Short	2,560 (K)
Shares Short P.Month	1,510 (K)

EPS	3.48
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	21.53
Profit Margin	9.1 %
Operating Margin	18.6 %
Return on Assets (ttm)	9.4 %
Return on Equity (ttm)	18.1 %
Qtrly Rev. Growth	31.2 %
Gross Profit (p.s.)	27.55
Sales Per Share	38.49
EBITDA (p.s.)	8.01
Qtrly Earnings Growth	3.9 %
Operating Cash Flow	569 (M)
Levered Free Cash Flow	155 (M)

PE Ratio	58.17
PEG Ratio	0
Price to Book value	9.4
Price to Sales	5.25
Price to Cash Flow	25.03

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.